MEIP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer...

Stats
Today's Volume	18 971.00
Average Volume	20 306.00
Market Cap	19.06M
EPS	$0 ( 2024-05-09 )
Last Dividend	$1.750 ( 2023-11-16 )
Next Dividend	$0 ( N/A )
P/E	0.730
ATR14	$0.0190 (0.64%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-17	Wood Steven D	Buy	3 100	Common Stock
2024-05-16	Flynn James P	Buy	7 900	Common Stock
2023-12-18	Flynn James P	Buy	10 000	Stock Option (Right to Buy)
2023-12-18	Flynn James P	Buy	6 700	Stock Option (Right to Buy)
2023-12-18	Wood Steven D	Buy	10 000	Stock Option (Right to Buy)

INSIDER POWER
91.86
Last 96 transactions
Buy: 9 843 993 \| Sell: 849 643

MEI Pharma Inc Correlation

10 Most Positive Correlations
PACB	0.962
VVOS	0.956
WBA	0.95
MVST	0.95
EVOK	0.949
INVZ	0.948
FWRD	0.948
RIVN	0.945
OPEN	0.944
CFFI	0.942

10 Most Negative Correlations
APXI	-0.94
ESTA	-0.936
DXJS	-0.929
ACGL	-0.928
OXSQ	-0.928
BSCO	-0.927
IBKR	-0.925
SWAV	-0.922
PNTG	-0.916
ADTH	-0.916

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MEI Pharma Inc Financials

Annual	2023
Revenue:	$48.82M
Gross Profit:	$47.00M (96.28 %)
EPS:	$-4.78

FY	2023
Revenue:	$48.82M
Gross Profit:	$47.00M (96.28 %)
EPS:	$-4.78

FY	2022
Revenue:	$40.70M
Gross Profit:	$39.46M (96.97 %)
EPS:	$-8.80

FY	2021
Revenue:	$25.54M
Gross Profit:	$24.13M (94.49 %)
EPS:	$-0.450

Financial Reports:

No articles found.

MEI Pharma Inc Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$1.750 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

MEI Pharma Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 5.63 - average (54.68%) | Divividend Growth Potential Score: 0 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$1.750	2023-11-16
Last Dividend	$1.750	2023-11-16
Next Dividend	$0	N/A
Payout Date	2023-12-06
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$1.750	--
Avg. Dividend % Per Year	11.67%	--
Score	4.8	--
Div. Sustainability Score	5.63
Div.Growth Potential Score	0
Div. Directional Score	2.63	--

Next Divdend (Est)
(2024-06-03)

$3.50 Estimate 2.50 %

Dividend Stability

0.20 Very Poor

Dividend Score

4.80

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2023	$1.750	35.00%
2024	$0	0.00%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
OXLC	Dividend Diamond	2023-12-14	Monthly	14	10.00%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend Royal	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.392	1.500	2.16	3.25	[0 - 0.5]
returnOnAssetsTTM	0.367	1.200	10.00	10.00	[0 - 0.3]
returnOnEquityTTM	0.483	1.500	5.74	8.61	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	6.17	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	5.88	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	0.246	1.500	9.74	10.00	[0.2 - 2]
debtRatioTTM	0.164	-1.500	7.27	-10.00	[0 - 0.6]
interestCoverageTTM	-1 726.31	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-6.57	2.00	-2.19	-4.38	[0 - 30]
freeCashFlowPerShareTTM	-6.57	2.00	-3.28	-6.57	[0 - 20]
debtEquityRatioTTM	0.229	-1.500	9.09	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.984	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.336	1.000	5.28	5.28	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-3.75	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0.937	0.800	7.09	5.67	[0.5 - 2]
Total Score				5.63

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	0.729	1.000	-0.0274	0	[1 - 100]
returnOnEquityTTM	0.483	2.50	7.26	8.61	[0.1 - 1.5]
freeCashFlowPerShareTTM	-6.57	2.00	-2.19	-6.57	[0 - 30]
dividendYielPercentageTTM	61.19	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-6.57	2.00	-2.19	-4.38	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0174	1.500	-3.22	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.656	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-0.361

MEI Pharma Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

MEI Pharma Inc

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.